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ABSTRACT
Although tremendous effort has been put into syn-
thetic libraries, most drugs on the market are still
10 natural compounds or derivatives thereof. There are
encyclopaedias of natural compounds, but the avail-
ability of these compounds is often unclear and cata-
logues from numerous suppliers have to be checked.
To overcome these problems we have compiled a
15 database of 50000 natural compounds from differ-
ent suppliers. To enable efficient identification of the
desired compounds, we have implemented substruc-
ture searches with typical templates. Starting points
forinsilicoscreeningsareabout2500well-knownand
20 classified natural compounds from a compendium
that we have added. Possible medical applications
can be ascertained via automatic searches for similar
drugs in a free conformational drug database con-
taining WHO indications. Furthermore, we have com-
25 puted about three million conformers, which are
deployed to account for the flexibilities of the com-
pounds when the 3D superposition algorithm that we
have developed is used. The SuperNatural Database
is publicly available at http://bioinformatics.charite.
30 de/supernatural. Viewing requires the free Chime-
plugin from MDL (Chime) or Java2 Runtime
Environment (MView), which is also necessary for
using Marvin application for chemical drawing.
INTRODUCTION
35 The world is full of natural products, but only a few existing
natural products are known and our understanding of the meta-
bolome is fragmentary. Nature invented a universe of sec-
ondary metabolites as ‘defense compounds’ against enemies
in predator–prey relationships. Concomitantly, strategies for
40 handling xenobiotics evolved, such as the multidrug resistance
efﬂux pump and the cytochrome P450 monooxygenases (1,2).
Tulp and Bohlin (3) hypothesize that when a natural com-
pound occurs in unrelated species, it must have an important
biological function, e.g. addressing a speciﬁc target, because
45 fortuitous productionofaparticularcompoundby totally unre-
lated species is extremely improbable (3). About 200 000
natural compounds are currently known and many more
will prove to be more than just ‘secondary metabolites’ (3).
Even though combinatorial synthesis is now producing mole-
50 cules that are drug-like in terms of size and property, these
molecules, in contrast to natural products, have not evolved
to interact with biomolecules (4). Natural compounds such as
brefelidin A, camptothecin, forskolin and immunophilins
often interfere with protein–protein interaction sites (5). Ana-
55 lysis of the properties of synthetic and natural compounds
compared to drugs revealed the distinctiveness of natural com-
pounds, especially concerning the diversity of scaffolds and
the large number of chiral centers (6). This may be one reason
why 50% of the drugs introduced to the market during the
60 last 20 years are derived directly or indirectly from natural
compounds (7). Although most drugs on the market have a
natural origin, their availability often remains unclear (8). The
percentage of new non-synthetic chemical entities in the area
of cancer remained at a yearly average of 62% over the period
65 of 1981–2002 (9). Some marine natural products are either in
or approaching Phase II/III clinical trials in cancer, analgesia,
allergy and cognitive diseases (10). The chemical diversity of
these compounds is tremendous and may offer inspiration for
innovations in the ﬁelds of medicine, nutrition, agrochemical
70 and life sciences (11).
THE DATABASE
Several commercial databases and databases of rare com-
pounds exist (12–14), but the SuperNatural Database is the
ﬁrst public resource containing 3D structures and conformers
75 of 45917 natural compounds, derivatives and analogues
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doi:10.1093/nar/gkj132purchasable from different suppliers. Currently, data from
eight suppliers are available, but we plan to add further sup-
pliers, compounds from which will be added on request (see
‘List ofSuppliers’on theSuperNaturalDatabasewebsite).The
5 2Dstructureofeach compound, provided by the suppliers,was
used to generate 3D structures (Discovery Studio, Accelrys
Inc., http://www.accelrys.com/dstudio). Using a chemistry
development kit (http://almost.cubic.uni-koeln.de/cdk/), ﬁn-
gerprints (966 bits, MACCS Keys) were calculated; each
10 bit of a ﬁngerprint represents functional groups (structural
ﬁngerprint). As a measure of 2D similarity we used the
Tanimoto coefﬁcient (15), which compares the bits of the
structural ﬁngerprints of two compounds. A Tanimoto coef-
ﬁcient of >0.85 indicates that a molecule has activities similar
15 to a lead compound (16). For better coverage of the com-
pounds and to ensure their ﬂexibility during usage of the
3D-superposition algorithm, about three million conformers
were evaluated (MedChem Explorer, Accelrys Inc., http://
www.accelrys.com/dstudio/ds_medchem). As a threshold
20 for conformer generation, 20 kcal/mol as a relative maximum
energy was set. This spacious threshold allows the user to
ﬁnd the best 3D superposition of two compounds even if
they contain several rotatable bonds. The pre-computed ﬁn-
gerprints are stored in a MySQL-database on a web server,
25 which is accessible via browser (see FAQ on the website for
the database schema).
Owing to the immense structural diversity of natural
compounds compared to synthetic compounds, an increased
spectrum of therapeutic activities can be covered. Natural
30 compounds can be classiﬁed by different criteria (see the
classiﬁcation list at ‘Search via known compounds’ on the
SuperNatural Database website):
(i) Classificationbystructuralcharacteristics:alkaloid, amino
acid, fatty acid, etc.
35 (ii) Classification by functional aspects: vitamin, hormone,
enzyme, etc.
To ﬁnd desired natural compounds, anumberof search options
were implemented:
40  As a starting point for screenings we compiled a searchable
compendium of about 2500 well-known natural compounds
characterized by a CAS-number (Chemical Abstracts),
which is useful to cross-referencing other databases. This
compendiumcontainssystematicnames,classificationcodes,
45 empiric formulae, mixtures and synonyms (Figure 1A).
 Similarity searches based on fingerprints and Tanimoto
coefficients are implemented in the SuperNatural Database
(Figure 1B).
 Another way to perform a similarity search is the Marvin
50 Applet, which allows the user to build or import a molecular
structureandcompareitwithcompoundsoftheSuperNatural
Database (Figure 1C).
 Furthermore, an algorithm developed in our group enables
3D-superpositions of two compounds to be made. The algo-
55 rithmcomparesallconformersoftwocompoundstofindthe
best structural alignment (17) (Figure 1E).
 To identify possible applications, the user can search for
similardrugsinthefreedrugdatabase(SuperDrugDatabase)
containing medical indications assigned by WHO (18).
About 300 natural compounds from the SuperNatural Data-
base are identical to active ingredients ofdrugs,and 8%(3600)
of the natural compounds are similar to essential marketed
drugs with Tanimoto coefﬁcients >0.85. For each natural com-
pound, information on different structural and chemical prop-
erties (DS Viewer, Property Calculator, http://www.accelrys.
com/dstudio) such as number of chiral centers, estimated logp,
surface area, etc. are precalculated and given in a separate
‘FULL INFO’ window (Figure 1D). For molecular visualiza-
tion of the compounds, the user needs the free Chime-Plugin
from MDL (available for Windows, SGI, Mac) or the Java2
Runtime Environment. Atomic coordinates of single or super-
imposed compounds are available for saving in Mol-format.
PRACTICAL APPROACHES USING THE
SIMILARITY SCREENING FUNCTION OF
THE SUPERNATURAL DATABASE
A detailed review of various approaches to similarity search-
ing was given by Willet et al. (19). Screenings for new bio-
active natural compounds on the basis of chemical similarity
to a known ligand depend on the similar property principle of
Johnson and Maggiora (20). As an example, we performed a
similarity screening in the SuperNatural Database with natural
compounds that are known drugs, from clinical trials or lead
compounds for drug development (Tables 1 and 2 and Sup-
plementary Data) (21). Our investigations showed that the
database contains compounds that have already been investi-
gated in clinical trials for different diseases (Table 1 and 2 and
Supplementary Data) and a great number of compounds with
calculated 2D similarities of >0.85 to the lead compounds.
The SuperNatural Database contains 289 natural compounds,
which are already known as drugs. Owing to the immense
structural and chemical variety of natural compounds, the
coverage of a great spectrum of diseases is possible, which
is conﬁrmed by the ATC classiﬁcations of the drugs (see ATC
classiﬁcation in the category statistics on the SuperNatural
website). There are 73 different ATC classes (three letter
abbreviations) covered by these 289 natural compounds.
The results show that the SuperNatural Database is an excel-
lent source for ﬁnding bioactive natural products.
AVAILABILITY
The database is publicly available at http://bioinformatics.
charite.de/supernatural. The data will be updated twice a year.
CONCLUSIONS AND FUTURE DIRECTIONS
The chemical diversity and unique properties of natural com-
pounds provide a promising starting-point for developing
innovations for scientiﬁc, medical and nutritional applications.
The SuperNatural Database is a free resource with embedded
screening functions for bioactive natural compounds. The
extension of the database allows the scientiﬁc community
simple access to a growing number of available natural
compounds.
Nucleic Acids Research, 2006, Vol. 34, Database issue D679Figure 1. Screenshots of the web-interface of the SuperNatural Database. (A) Navigation frame and text query options for performing a search via known natural
compounds.(B)Queryresultswiththeoptionfora3Dsuperposition.The2Dsimilarityqueryshowstwocompounds,whichhavea2Dsimilarityof100.00and87.41
to the lead-structure. The compounds can be rotated (left mouse button), different display styles are available (right mouse button) and more detailed information
concerning the properties of each structure can be obtained by use of the Properties button. Both compounds are available from the supplier MicroSource.
(C) Screenshot of the Java applet Marvin, which allows upload or drawing of own structures for similarity searches in the SuperNatural Database. (D) Calculated
properties for one structure. (E) Results of a 3D superposition. All conformations of both structures are superimposed and the best superposition is displayed. The
tableseparatelydepictsthestructuresandthesuperpositionofthecorrespondingconformationsinthemiddle.The(superimposed)3Dstructurescanbesavedbyright
clicking on the molecule. Also, information is given about the number of superimposed atoms and the root mean square distance.
D680 Nucleic Acids Research, 2006, Vol. 34, Database issueTable1.Well-knownnaturalcompounds(drugs,leadcompoundsfordrugs orcompoundsin clinicaltrials)withantibacterial,antifungal,antiparasiticandantiviral
effects and similar compounds (tanimoto >0.85) from the SuperNatural Database




Antibacterial/J01* (antibacterials for sytemic use)
Cephalosporin 20 Lead compound of cefalotin (21)
Erythromycin 15 Lead compound of flurithromycin (21)
(Oxy-, chlor-) tetracycline 27 Lead compound minocycline (21)
Antifungal/J02* (antimycotics for systemic use)
Echinocandin B 4 Lead compound of caspofungin (22)
Antiparasitic/A07* (antidiarrheals, intestinal anti-inflammatory, anti-infective agents) P01* (antiprotozoals)
Paromomycin 16 Active agent of paromomycin (23)
Artemisinin 7 Active agent of Artemisinin (24)
Antiviral/J05* (antivirals for systemic use)
Betulinic acid 41 Phase I clinical trials (21)
*Anatomical Therapeutic Chemical (ATC) classification code generated by the World Health Organization (WHO) describes the therapeutic subgroup (25).
Nucleic Acids Research, 2006, Vol. 34, Database issue D681SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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